MCPHS / Moderna - Global Regulatory Science, Post PharmD Fellow
Location: Cambridge, Massachusetts
Required Education: PharmD
The Global Regulatory Science (GRS) department drives rapid and efficient development of molecules and medicinal products derived from an mRNA platform. We hope to ensure patient access to transformative therapies, while building a sustainable and resilient function within Moderna. The fellow will join the Global Regulatory Science team in Cambridge, Massachusetts.
The 2-year Global Regulatory Science Program will provide PharmD graduates the opportunity to gain rapid experience in the pharmaceutical industry with a focus on Regulatory Science while working on diverse projects to deepen their understanding of product development.
The fellow will focus on Regulatory Strategy and take part in projects covering 2-3 regulatory specialties, including:
Regulatory Advertising and Promotion
International Regulatory Affairs
Projects will be assigned based on the fellow’s areas of interest and available opportunities to build the fellow’s competencies as a regulatory professional. Additionally, the fellow will have the option to take part in a 1-3 month rotation in another department outside of Global Regulatory Science at Moderna.
The MCPHS application portal (SMApply) will open on Monday, October 3rd, 2022. Applicants must upload the following application materials to the online portal (https://mcphs.smapply.io) no later than Friday, November 11th, 2022:
Letter of intent
Unofficial college transcript
Contact information of three references. References will receive an electronic recommendation form to complete separately.
Three recommendation evaluation forms must be submitted no later than December 1st, 2022 via the online portal. This is NOT a letter of recommendation but an online form that the recommender will receive for completion from SMApply.
Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via PPS to schedule interviews.
Incomplete applications WILL NOT be reviewed. ASHP Clinical Midyear Meeting interviews CANNOT be scheduled until these materials have been submitted. Please keep in mind that this is a competitive process and applicants are encouraged to complete their applications as soon as possible.
Rolling Application Review & Interviews
All submitted applications will be reviewed on a rolling basis. Interviews will also be offered on a rolling basis and opportunities are limited. Priority will be given to those applicants who apply early, well in advance of the deadline.
Rolling interviews will start mid-October with pre-screens and a mixture of interview rounds which will conclude in December at the end of the ASHP Midyear Clinical Meeting. Candidates will be notified if selected for an interview.
ASHP Midyear & Onsite Interviews
The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in Las Vegas. Applicants are strongly encouraged to attend. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.
Top candidates may be invited for interviews at the sponsoring company’s location pending COVID – 19 restrictions.
Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, MCPHS in conjunction with the Academic Industry Fellowship Alliance (AIFA), has agreed to extend offers for Fellowships no earlier than December 7, 2022.
Final candidates will be required to go through additional screening/onboarding as required by MCPHS.
The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.
Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
All candidates must have authorization to work in the United States throughout the duration of the two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.